Thus, mGluR2 and mGluR3 can be considered targets for searching for new anti-neurodegenerative compounds, and mGluR2 blockade and mGluR3 activation can be used as a strategy for the treatment of AD [86]. Here, GRM2 is linked to Alzheimer disease.